Celltrion Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Celltrion ist ein dividendenzahlendes Unternehmen mit einer aktuellen Rendite von 0.28%.

Wichtige Informationen

0.3%

Dividendenausschüttung

20%

Ausschüttungsquote

Durchschnittlicher Branchenertrag	0.5%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	₩500.000
Gewinn pro Aktie	₩1.91k
Erwartete Dividendenrendite in 3 Jahren	0.3%

Aktuelle Dividendenentwicklung

Recent updates

Here's What Celltrion, Inc.'s (KRX:068270) Shareholder Ownership Structure Looks Like

Mar 15

Is Celltrion's (KRX:068270) Share Price Gain Of 208% Well Earned?

Feb 24

Celltrion (KRX:068270) Has A Rock Solid Balance Sheet

Feb 03

Is Celltrion, Inc.'s (KRX:068270) Latest Stock Performance A Reflection Of Its Financial Health?

Jan 13

Does Celltrion (KRX:068270) Deserve A Spot On Your Watchlist?

Dec 23

Are Institutions Heavily Invested In Celltrion, Inc.'s (KRX:068270) Shares?

Dec 02

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: A068270 zahlt keine nennenswerte Dividende für den Markt KR, daher muss nicht geprüft werden, ob die Zahlungen stabil sind.

Wachsende Dividende: A068270 zahlt keine nennenswerte Dividende für den Markt KR, daher muss nicht geprüft werden, ob die Zahlungen steigen.

Dividendenrendite im Vergleich zum Markt

Celltrion Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von A068270 im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (A068270)	0.3%
Untere 25 % des Marktes (KR)	1.1%
Markt Top 25 % (KR)	3.7%
Branchendurchschnitt (Biotechs)	0.5%
Analystenprognose in 3 Jahren (A068270)	0.3%

Bemerkenswerte Dividende: A068270Die Dividende des Unternehmens (0.28%) ist im Vergleich zu den unteren 25 % der Dividendenzahler auf dem Markt KR (1.01%) nicht bemerkenswert.

Hohe Dividende: A068270Die Dividende des Unternehmens (0.28%) ist im Vergleich zu den besten 25 % der Dividendenzahler auf dem Markt KR (3.5%) niedrig.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: A068270 zahlt keine nennenswerte Dividende für den Markt KR.

Barausschüttung an die Aktionäre

Cashflow-Deckung: A068270 zahlt keine nennenswerte Dividende für den Markt KR.

Celltrion Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Upcoming dividend of ₩500 per share at 0.3% yield

Upcoming dividend of ₩375 per share

Recent updates

Here's Why Celltrion (KRX:068270) Has A Meaningful Debt Burden

Celltrion Showcases Promising Results in Phase III study for CT-P47, A Biosimilar Candidate of Roactemra® (Tocilizumab) in Patients with Rheumatoid Arthritis (RA) at EULAR 2024

Celltrion Receives European Commission Approval of Omlyclo® (CT-P39), the First and Only Omalizumab Biosimilar Approved in Europe

Estimating The Intrinsic Value Of Celltrion, Inc. (KRX:068270)

First quarter 2024 earnings released: EPS: ₩108 (vs ₩1,156 in 1Q 2023)

Now 21% overvalued after recent price rise

Celltrion, Inc. (KRX:068270) Not Flying Under The Radar

Consensus EPS estimates fall by 14%

Celltrion's (KRX:068270) Profits May Not Reveal Underlying Issues

Full year 2023 earnings released: EPS: ₩3,759 (vs ₩3,664 in FY 2022)

We Think Celltrion (KRX:068270) Can Stay On Top Of Its Debt

Consensus EPS estimates fall by 16%

Celltrion, Inc., Annual General Meeting, Mar 26, 2024

Celltrion Presents New Two-Year Data for Subcutaneous Injectiximab (CT-P13 SC) in Inflammative Bowel Disease (IBD)

New minor risk - Shareholder dilution

Investor sentiment improves as stock rises 22%

Upcoming dividend of ₩500 per share at 0.3% yield

Consensus EPS estimates fall by 19%

Celltrion, Inc. to Report Nine Months, 2023 Results on Nov 07, 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Celltrion, Inc. agreed to acquire a 64.46% stake in Celltrion Healthcare Co., Ltd. (KOSDAQ:A091990) for KRW 6.7 billion

First quarter 2023 earnings released: EPS: ₩1,156 (vs ₩756 in 1Q 2022)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Celltrion Healthcare Announces Canadian Approval of Vegzelma® (Bevacizumab for Injection) for the Treatment of Five Types of Cancer

Upcoming dividend of ₩375 per share

Now 20% undervalued after recent price drop

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Consensus forecasts updated

Second quarter 2022 earnings released: EPS: ₩1,328 (vs ₩907 in 2Q 2021)

Price target increased to ₩210,861

Consensus forecasts updated

Investor sentiment improved over the past week

Price target decreased to ₩194,520

Less than half of directors are independent

Now 20% undervalued after recent price drop

Price target decreased to ₩218,897

Full year 2021 earnings: EPS misses analyst expectations

Consensus revenue estimates increase by 10%

Celltrion, Inc Ordinary Shares to Be Deleted from Other OTC

Price target decreased to ₩277,071

Third quarter 2021 earnings released: EPS ₩992 (vs ₩1,251 in 3Q 2020)

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS ₩919 (vs ₩1,013 in 2Q 2020)

Consensus EPS estimates fall to ₩4,214

Here's Why I Think Celltrion (KRX:068270) Is An Interesting Stock

Celltrion, Inc. Receives FDA Emergency Use Authorization for Point of Care Antigen Rapid Test Kit – DiaTrust COVID-19 Ag Rapid Test

Robust Earnings May Not Tell The Whole Story For Celltrion (KRX:068270)

Here's What Celltrion, Inc.'s (KRX:068270) Shareholder Ownership Structure Looks Like

Is Celltrion's (KRX:068270) Share Price Gain Of 208% Well Earned?

New 90-day low: ₩300,500

Celltrion, Inc., Annual General Meeting, Mar 26, 2021

Celltrion Develops Tailored Neutralising Antibody Cocktail Treatment with CT-P59 to Tackle COVID-19 Variant Spread Using Its Antibody Development Platform

Celltrion’s COVID-19 Treatment Candidate Receives Korean MFDS Conditional Marketing Authorisation

Celltrion (KRX:068270) Has A Rock Solid Balance Sheet

Celltrion Group Announces Positive Top-Line Efficacy and Safety Data from Global Phase II/III Clinical Trial of COVID-19 Treatment Candidate CT-P59

Is Celltrion, Inc.'s (KRX:068270) Latest Stock Performance A Reflection Of Its Financial Health?

Does Celltrion (KRX:068270) Deserve A Spot On Your Watchlist?

Are Institutions Heavily Invested In Celltrion, Inc.'s (KRX:068270) Shares?

Celltrion, Inc. (KOSE:A068270) completed the acquisition of portfolio of select non-core otc and prescription pharmaceutical products exclusively in Asia Pacific from Takeda Pharmaceutical Company Limited (TSE:4502).

Celltrion Completes Enrolment for Global Phase II Clinical Trial with COVID-19 Treatment Candidate CT-P59

New 90-day high: ₩330,000

Celltrion Presents Efficacy and Safety Data for Potential Covid-19 Treatment Candidate Ct-P59 in Patients with Mild Symptoms

New 90-day low: ₩245,500

New 90-day low: ₩278,500

Price target raised to ₩284,353

Stabilität und Wachstum des Zahlungsverkehrs

Dividendenrendite im Vergleich zum Markt

Gewinnausschüttung an die Aktionäre

Barausschüttung an die Aktionäre

Entdecken Sie dividendenstarke Unternehmen